Clinuvel Pharmaceuticals Limited (ASX:CUV) to Issue Final Dividend of $0.05

Clinuvel Pharmaceuticals Limited (ASX:CUV) announced a final dividend on Wednesday, September 4th, MarketIndexAU reports. Stockholders of record on Thursday, September 19th will be given a dividend of 0.05 per share on Thursday, September 19th. This represents a dividend yield of 0.33%. The ex-dividend date of this dividend is Wednesday, September 4th.

Clinuvel Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.43, a quick ratio of 10.03 and a current ratio of 8.81.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).